Myastenia gravis: features of epidemiology, pathogenesis, treatment and relation to thymomas

Мyasthenia gravis is a common disease, for adequate treatment of which early detection, knowledge of its clinical manifestations and possible methods of therapy is required. This review provides up-to-date information regarding the issues of myasthenia gravis. The aim of the paper: to systematize the latest scientific data on the pathogenesis, genetic characteristics, methods of treatment of myasthenia gravis, as well as to identify the relationship between myasthenia gravis and other diseases. The following databases were used to search for published studies: Pubmed, Web of Science, EBSCOhost and Scopus. The search was carried out in the time period from the date of establishment of the corresponding database until October 2022. Following search terms were used: “myasthenia gravis”, “myasthenia treatment”, “myasthenia epidemiological features”, “myasthenia and thymoma “myasthenia pathogenesis””. Тhe main studies on the epidemiology of myasthenia gravis are indicated, the key clinical forms and their pathogenetic characteristics, the relationship between myasthenia gravis and thymoma, and the main methods of treatment are also given.

1. Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. J Clin Med. 2021;10(11):2235. https://doi.org/10.3390/jcm10112235

2. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116(11):2843–2854. https://doi.org/10.1172/JCI29894

3. Avidan N, Le Panse R, Berrih-Aknin S, Miller A. Genetic basis of myasthenia gravis — a comprehensive review. J Autoimmun. 2014;52:146–153. https://doi.org/10.1016/j.jaut.2013.12.001

4. Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021;14(1):7–16. https://doi.org/10.25122/jml-2020-0145

5. Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B. Diagnostic and clinical classifi cation of autoimmune myasthenia gravis. J Autoimmun. 2014;48–49:143–148. https://doi.org/10.1016/j.jaut.2014.01.003

6. Cleanthous S, Mork AC, Regnault A, Cano S, Kaminski HJ, Morel T. Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease. Orphanet J Rare Dis. 2021;16(1):457. https://doi.org/10.1186/s13023-021-02064-0

7. Isbister CM, Mackenzie PJ, Anderson D, Wade NK, Oger J. Co-occurrence of multiple sclerosis and myasthenia gravis in British Columbia. Mult Scler. 2003;9(6):550–553. https://doi.org/10.1191/1352458503ms964oa

8. Deymeer F. History of Myasthenia Gravis Revisited. Noro Psikiyatr Ars. 2020;58(2):154–162. https://doi.org/10.29399/npa.27315

9. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141–149. https://doi.org/10.1002/mus.20950

10. Hehir MK, Silvestri NJ. Generalized Myasthenia Gravis: Classifi cation, Clinical Presentation, Natural History, and Epidemiology. Neurol Clin. 2018;36(2):253–260. https://doi.org/10.1016/j.ncl.2018.01.002

11. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010;10:46. https://doi.org/10.1186/1471-2377-10-46

12. Santos E, Coutinho E, Moreira I, Silva AM, Lopes D, Costa H et al. Epidemiology of myasthenia gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases. Muscle Nerve. 2016;54(3):413–421. https://doi.org/10.1002/mus.25068

13. Hatкhe YA, Zabolotskih NV, Terpelec SA. Epidemiological and population aspects of myasthenia gravis in the Krasnodar district. Neuromuscular diseases (Nervno-myshechnye bolezni). 2018;8(1):28–33. (In Russ.). https://doi.org/10.17650/2222-8721-2018-8-1-28-33

14. Ishmuhametova AT, Musin RG, Hidiyatova IM, Magzhanov RV. Epidemiological study of myasthenia gravis in the Republic of Bashkortostan. Neurological Journal (Nevrologicheskiy Zhurnal). 2006;11(6):16–21. (In Russ.). URL: https://www.elibrary.ru/item.asp?id=9313415

15. Romanova TV. Epidemiological study of myasthenia gravis in the Samara region. Saratov Scientific Medical Journal (Saratovskij nauchno-medicinskij zhurnal). 2012;8(1):091–095. (In Russ.). URL: https://ssmj.ru/2012/1/091

16. Zaslavsky LG, Hurshilov AB. Main clinic and epidemiological factors of myasthenia in Leningrad region. The Scientifi c Notes of the Pavlov University (Uchenye zapiski Sankt-Peterburgskogo gosudarstvennogo medicinskogo universiteta imeni akademika I.P. Pavlova). 2015;22(4):40–43. (In Russ.). https://doi.org/10.24884/1607-4181-2015-22-4-40-43

17. Koneczny I, Herbst R. Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture. Cells. 2019;8(7):671. https://doi.org/10.3390/cells8070671

18. Uzawa A, Kuwabara S, Suzuki S, Imai T, Murai H, Ozawa Y et al. Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol. 2021;203(3):366–374. https://doi.org/10.1111/cei.13546

19. Lee JY, Stathopoulos P, Gupta S, Bannock JM, Barohn RJ, Cotzomi E et al. Compromised fi delity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis. Ann Clin Transl Neurol. 2016;3(6):443–454. https://doi.org/10.1002/acn3.311

20. Vander Heiden JA, Stathopoulos P, Zhou JQ, Chen L, Gilbert TJ, Bolen CR et al. Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing. J Immunol. 2017;198(4):1460–1473. https://doi.org/10.4049/jimmunol.1601415

21. Takaba H, Takayanagi H. The Mechanisms of T Cell Selection in the Thymus. Trends Immunol. 2017;38(11):805–816. https://doi.org/10.1016/j.it.2017.07.010

22. Poëa-Guyon S, Christadoss P, Le Panse R, Guyon T, De Baets M, Wakkach A et al. Eff ects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J Immunol. 2005;174(10):5941–5949. https://doi.org/10.4049/jimmunol.174.10.5941

23. Dragin N, Bismuth J, Cizeron-Clairac G, Biferi MG, Berthault C, Serraf A et al. Estrogen-mediated downregulation of AIRE influences sexual dimorphism in autoimmune diseases. J Clin Invest. 2016;126(4):1525–1537. https://doi.org/10.1172/JCI81894

24. Truff ault F, de Montpreville V, Eymard B, Sharshar T, Le Panse R, Berrih-Aknin S. Thymic Germinal Centers and Corticosteroids in Myasthenia Gravis: an Immunopathological Study in 1035 Cases and a Critical Review. Clin Rev Allergy Immunol. 2017;52(1):108–124. https://doi.org/10.1007/s12016-016-8558-3

25. Vrolix K, Fraussen J, Losen M, Stevens J, Lazaridis K, Molenaar PC et al. Clonal heterogeneity of thymic B cells from earlyonset myasthenia gravis patients with antibodies against the acetylcholine receptor. J Autoimmun. 2014;52:101–112. https://doi.org/10.1016/j.jaut.2013.12.008

26. Vinuesa CG, Linterman MA, Yu D, MacLennan IC. Follicular Helper T Cells. Annu Rev Immunol. 2016;34:335–368. https://doi.org/10.1146/annurev-immunol-041015-055605

27. Gradolatto A, Nazzal D, Truff ault F, Bismuth J, Fadel E, Foti M, Berrih-Aknin S. Both Treg cells and Tconv cells are defective in the Myasthenia gravis thymus: roles of IL-17 and TNF-α. J Autoimmun. 2014;52:53–63. https://doi.org/10.1016/j.jaut.2013.12.015

28. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev. 2009;89(1):73–120. https://doi.org/10.1152/physrev.00015.2008

29. Tzartos SJ, Barkas T, Cung MT, Mamalaki A, Marraud M, Orlewski P et al. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev. 1998;163:89–120. https://doi.org/10.1111/j.1600-065x.1998.tb01190.x

30. Kordas G, Lagoumintzis G, Sideris S, Poulas K, Tzartos SJ. Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients [published correction appears in PLoS One. 2015;10(1):e0117673] [published correction appears in PLoS One. 2015;10(3):e0120947]. PLoS One. 2014;9(9):e108327. Published 2014 Sep 26. https://doi.org/10.1371/journal.pone.0108327

31. Fostieri E, Beeson D, Tzartos SJ. The conformation of the main immunogenic region on the alpha-subunit of muscle acetylcholine receptor is affected by neighboring receptor subunits. FEBS Lett. 2000;481(2):127–130. https://doi.org/10.1016/s0014-5793(00)01980-3

32. Morgan BP, Chamberlain-Banoub J, Neal JW, Song W, Mizuno M, Harris CL. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol. 2006;146(2):294–302. https://doi.org/10.1111/j.1365-2249.2006.03205.x

33. Rødgaard A, Nielsen FC, Djurup R, Somnier F, Gammeltoft S. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin Exp Immunol. 1987;67(1):82–88. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1542559/

34. Morgan BP, Chamberlain-Banoub J, Neal JW, Song W, Mizuno M, Harris CL. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol. 2006;146(2):294–302. https://doi.org/10.1111/j.1365-2249.2006.03205.x

35. Kim N, Stiegler AL, Cameron TO, Hallock PT, Gomez AM, Huang JH, et al. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell. 2008;135(2):334–342. https://doi.org/10.1016/j.cell.2008.10.002

36. Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36–40. https://doi.org/10.1002/mus.22006

37. Cole RN, Reddel SW, Gervásio OL, Phillips WD. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol. 2008;63(6):782–789. https://doi.org/10.1002/ana.21371

38. Niks EH, van Leeuwen Y, Leite MI, Dekker FW, Wintzen AR, Wirtz PW et al. Clinical fl uctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J Neuroimmunol. 2008;195(1–2):151–156. https://doi.org/10.1016/j.jneuroim.2008.01.013

39. Poulas K, Koutsouraki E, Kordas G, Kokla A, Tzartos SJ. Anti- MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine. J Neuroimmunol. 2012;250(1–2):94–98. https://doi.org/10.1016/j.jneuroim.2012.05.011

40. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classifi cation and therapeutic strategies. Lancet Neurol. 2015;14(10):1023–1036. https://doi.org/10.1016/S1474-4422(15)00145-3

41. Cortés-Vicente E, Gallardo E, Martínez MÁ, Díaz-Manera J, Querol L, Rojas-García R, Illa I. Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin. JAMA Neurol. 2016;73(9):1099–1104. https://doi.org/10.1001/jamaneurol.2016.2032

42. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol. 2011;69(2):418–422. https://doi.org/10.1002/ana.22312

43. Rivner MH, Quarles BM, Pan JX, Yu Z, Howard JF Jr, Corse A et al. Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: A multicenter study. Muscle Nerve. 2020;62(3):333–343. https://doi.org/10.1002/mus.26985

44. Zhang B, Tzartos JS, Belimezi M, Ragheb S, Bealmear B, Lewis RA et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol. 2012;69(4):445–451. https://doi.org/10.1001/archneurol.2011.2393

45. Zagoriti Z, Kambouris ME, Patrinos GP, Tzartos SJ, Poulas K. Recent advances in genetic predisposition of myasthenia gravis. Biomed Res Int. 2013;2013:404053. https://doi.org/10.1155/2013/404053

46. Pirskanen R. Genetic aspects in myasthenia gravis. A family study of 264 Finnish patients. Acta Neurol Scand. 1977;56(5):365–388 URL: https://pubmed.ncbi.nlm.nih.gov/596124/

47. Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA et al. A genome-wide association study of myasthenia gravis. JAMA Neurol. 2015;72(4):396–404. https://doi.org/10.1001/jamaneurol.2014.4103

48. Carlsson B, Wallin J, Pirskanen R, Matell G, Smith CI. Diff erent HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis. Immunogenetics. 1990;31(5–6):285–290. https://doi.org/10.1007/BF02115001

49. Horton R, Gibson R, Coggill P, Miretti M, Allcock RJ, Almeida J et al. Variation analysis and gene annotation of eight MHC haplotypes: the MHC Haplotype Project. Immunogenetics. 2008;60(1):1–18. https://doi.org/10.1007/s00251-007-0262-2

50. From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR), Society of NeuroInterventional Surgery (SNIS), and World Stroke Organization (WSO), Sacks D, Baxter B, Campbell BCV, Carpenter JS, Cognard C, Dippel D, et al. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke. 2018;13(6):612–632. https://doi.org/10.1177/1747493018778713

51. Fernández-Mestre MT, Vargas V, Montagnani S, Cotúa M, Ogando V, Layrisse Z. HLA class II and class I polymorphism in Venezuelan patients with myasthenia gravis. Hum Immunol. 2004;65(1):54–59. https://doi.org/10.1016/j.humimm.2003.10.003

52. Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry. 1989;52(10):1121–1127. https://doi.org/10.1136/jnnp.52.10.1121

53. Hong YH, Kwon SB, Kim BJ, Kim BJ, Kim SH, Kim JK et al. Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. J Neurol Sci. 2008;273(1–2):10–14. https://doi.org/10.1016/j.jns.2008.05.023

54. Hendricks TM, Bhatti MT, Hodge DO, Chen JJ. Incidence, Epidemiology, and Transformation of Ocular Myasthenia Gravis: A Population-Based Study [published correction appears in Am J Ophthalmol. 2020 Jul 3;]. Am J Ophthalmol. 2019;205:99–105. https://doi.org/10.1016/j.ajo.2019.04.01755. Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375(26):2570–2581. https://doi.org/10.1056/NEJMra1602678

55. Sih M, Soliven B, Mathenia N, Jacobsen J, Rezania K. Headdrop: A frequent feature of late-onset myasthenia gravis. Muscle Nerve. 2017;56(3):441–444. https://doi.org/10.1002/mus.25526

56. Ciafaloni E. Myasthenia Gravis and Congenital Myasthenic Syndromes. Continuum (Minneap Minn). 2019;25(6):1767–1784. https://doi.org/10.1212/CON.0000000000000800

57. Grob D. Course and management of myasthenia gravis. J Am Med Assoc. 1953;153(6):529–532. https://doi.org/10.1001/jama.1953.02940230001001

58. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60(12):1978–1980. https://doi.org/10.1212/01.wnl.0000065882.63904.53

59. Pasnoor M, Wolfe GI, Nations S, Trivedi J, Barohn RJ, Herbelin L et al. Clinical fi ndings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve. 2010;41(3):370–374. https://doi.org/10.1002/mus.21533

60. Rivner MH, Liu S, Quarles B, Fleenor B, Shen C, Pan J, Mei L. Agrin and low-density lipoprotein-related receptor protein 4 antibodies in amyotrophic lateral sclerosis patients. Muscle Nerve. 2017;55(3):430–432. https://doi.org/10.1002/mus.25438

61. Tzartos JS, Zisimopoulou P, Rentzos M, Karandreas N, Zouvelou V, Evangelakou P et al. LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. Ann Clin Transl Neurol. 2014;1(2):80–87. https://doi.org/10.1002/acn3.26

62. Weksler B, Lu B. Alterations of the immune system in thymic malignancies. J Thorac Oncol. 2014;9(9Suppl2):S137–S142. https://doi.org/10.1097/JTO.0000000000000299

63. Punga AR, Maddison P, Heckmann JM, Guptill JT, Evoli A. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):176–188. https://doi.org/10.1016/S1474-4422(21)00297-0

64. Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016;87(4):419–425. https://doi.org/10.1212/WNL.0000000000002790

65. Detterbeck F, French CA, Hornick JL, Inagaki H, Jain D, Lazar AJ et al. The 2021 WHO Classifi cation of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors? J Thorac Oncol. 2022;17(2):200–213. https://doi.org/10.1016/j.jtho.2021.10.010

66. Lefeuvre CM, Payet CA, Fayet OM, Maillard S, Truff ault F, Bondet V et al. Risk factors associated with myasthenia gravis in thymoma patients: The potential role of thymic germinal centers. J Autoimmun. 2020;106:102337. https://doi.org/10.1016/j.jaut.2019.102337

67. Yamada Y, Yoshida S, Iwata T, Suzuki H, Tagawa T, Mizobuchi T et al. Risk factors for developing postthymectomy myasthenia gravis in thymoma patients. Ann Thorac Surg. 2015;99(3):1013–1019. https://doi.org/10.1016/j.athoracsur.2014.10.068

68. Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114–122. https://doi.org/10.1212/WNL.0000000000011124

69. Ye B, Tantai JC, Ge XX, Li W, Feng J, Cheng M et al. Surgical techniques for early-stage thymoma: video-assisted thoracoscopic thymectomy versus transsternal thymectomy. J Thorac Cardiovasc Surg. 2014;147(5):1599–1603. https://doi.org/10.1016/j.jtcvs.2013.10.053

70. Xi J, Wang L, Yan C, Song J, Song Y, Chen J et al. The Cancer Genome Atlas dataset-based analysis of aberrantly expressed genes by GeneAnalytics in thymoma associated myasthenia gravis: focusing on T cells. J Thorac Dis. 2019;11(6):2315–2323. https://doi.org/10.21037/jtd.2019.06.01

71. De Rosa A, Fornili M, Maestri Tassoni M, Guida M, Baglietto L, Petrucci L et al. Thymoma-associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma. Thorac Cancer. 2021;12(1):106–113. https://doi.org/10.1111/1759-7714.13724

72. Szczudlik P, Szyluk B, Lipowska M, Ryniewicz B, Kubiszewska J, Dutkiewicz M et al. Antititin antibody in early- and late-onset myasthenia gravis. Acta Neurol Scand. 2014;130(4):229–233. https://doi.org/10.1111/ane.12271

73. Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology. 2001;57(9):1579–1582. https://doi.org/10.1212/wnl.57.9.1579

74. Gastaldi M, De Rosa A, Maestri M, Zardini E, Scaranzin S, Guida M et al. Acquired neuromyotonia in thymoma-associated myasthenia gravis: a clinical and serological study. Eur J Neurol. 2019;26(7):992–999. https://doi.org/10.1111/ene.13922

75. Masuda T, Motomura M, Utsugisawa K, Nagane Y, Nakata R, Tokuda M et al. Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2012;83(9):935–940. https://doi.org/10.1136/jnnp-2012-302705

76. Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019;15(2):113–124. https://doi.org/10.1038/s41582-018-0110-z

77. Pikin OV, Ryabov AB, Shcherbakova NI, Glushko VA, Kolbanov KI, Barmin VV et al. Rethymectomy in patients with myasthenia gravis and recurrent thymoma. Pirogov Russian Journal of Surgery (Khirurgiya. Zurnal im. N.I. Pirogova). 2021;9:27–33. (In Russ.). https://doi.org/10.17116/hirurgia202109127

78. Shevchenko YL, Vetshev PS, Sanadze AG, Ablitsov AYu, Sidnev DV, Dedaev SI, Magomedov B. Antibodies to the acetylcholine receptor in assessing the eff ectiveness of thymectomy in patients with generalized myasthenia gravis. Bulletin of the National Medical and Surgical Center named after N.I. Pirogov (Vestnik Nacionalnogo mediko-hirurgicheskogo Centra im. N.I. Pirogova). 2011;6(4):15–19. (In Russ.).

79. Sanadze AG. Criteria for the diagnosis of myasthenia gravis. Diseases of the nervous system: mechanisms of development, diagnosis and treatment (Bolezni nervnoj sistemy: mekhanizmy razvitiya, diagnostika i lechenie). 2017:107–131. (In Russ.).

80. Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of Myasthenia Gravis. Neurol Clin. 2018;36(2):311–337. https://doi.org/10.1016/j.ncl.2018.01.011

81. Díaz-Manera J, Martínez-Hernández E, Querol L, Klooster R, Rojas- García R, Suárez-Calvet X et al. Long-lasting treatment eff ect of rituximab in MuSK myasthenia. Neurology. 2012;78(3):189–193. https://doi.org/10.1212/WNL.0b013e3182407982

82. Di Stefano V, Lupica A, Rispoli MG, Di Muzio A, Brighina F, Rodolico C. Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psychiatry. 2020;91(4):392–395. https://doi.org/10.1136/jnnp-2019-322606

83. Hain B, Jordan K, Deschauer M, Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve. 2006;33(4):575–580. https://doi.org/10.1002/mus.20479

84. Shcherbakova NI, Suponeva NA, Shvedkov VV, Shabalina AA, Kostyreva MV, Rudnichenko VA, Galkina OI. Russian experience of successful use of rituximab in refractory forms of myasthenia gravis. Neuromuscular diseases (Nervno-myshechnye bolezni). 2015;5(3):50–61. (In Russ.). https://doi.org/10.17650/2222-8721-2015-5-3-50-61